NPM1-ALK Overexpression-Driven Toxicity in ALCL Is Partner Dependent and Driven by Phosphorylation of Novel Substrates Leading to Overstimulation of Biosynthetic Pathways

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_12
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

The ALK Inhibitor PF-06463922 Is Effective as a Single Agent in Neuroblastoma Driven by Expression of ALK and MYCN

DMM Disease Models and Mechanisms
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
2016English

Significance of Pathways Leading to RhoC Overexpression in Breast Cancer

2005English

Cisplatin-Induced Ototoxicity in Rats Is Driven by RIP3-Dependent Necroptosis

Cells
2019English

The Heterogeneous Landscape of ALK Negative ALCL

Oncotarget
Oncology
2017English

STAT3 Mutation Is Associated With STAT3 Activation in CD30+ ALK− ALCL

Cancers
Cancer ResearchOncology
2020English

Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion

American Journal of Pathology
Forensic MedicinePathology
2018English

BCL6-Driven Lymphoma Is Dependent on LSD1 Corepression

Cancer Discovery
Oncology
2018English

Repotrectinib (TPX-0005), Effectively Reduces Growth of ALK Driven Neuroblastoma Cells

Scientific Reports
Multidisciplinary
2019English

Adolescents' Risk-Taking Behavior Is Driven by Tolerance to Ambiguity

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy